The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group

Durvalumab (IMFINZI®), FLOT, mFOLFOX (Folinsäure, 5-Fluorouracil (5-FU), Docetaxel, Oxaliplatin)

Status: In Rekrutierung

Klinische Settings

Beteiligte

Identifier

Kontakt